Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

BACKGROUND: Direct comparisons between lamivudine plus bPIs and lamivudine plus dolutegravir as maintenance strategies in virologically-suppressed HIV positive patients are lacking. METHODS: Time to treatment discontinuation (TD) and virological failure (VF) were compared in a cohort of HIV+ patient...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Infect Dis
Egile Nagusiak: Borghetti, Alberto, Lombardi, Francesca, Gagliardini, Roberta, Baldin, Gianmaria, Ciccullo, Arturo, Moschese, Davide, Emiliozzi, Arianna, Belmonti, Simone, Lamonica, Silvia, Montagnani, Francesca, Visconti, Elena, De Luca, Andrea, Di Giambenedetto, Simona
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2019
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6335713/
https://ncbi.nlm.nih.gov/pubmed/30654739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-018-3666-8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak